Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XMAB942 in Healthy Adults and Patients with Moderate-to-Severe Ulcerative Colitis
2025-522702-21-00Phase 2Authorised
- Sponsor
- Xencor
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing XMAB942 with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Planned start Jan 2026; status: authorised.
02
Drugs
XmAb942
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-522702-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522702-21-00.